bazedoxifene has been researched along with Pancreatic Neoplasms in 3 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 3 (100.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Chen, X; Lin, J; Su, GH; Tian, J | 1 |
| Fu, S; Lin, J | 1 |
| Cao, Y; Li, C; Lin, J; Wu, X; Xiao, H | 1 |
3 other study(ies) available for bazedoxifene and Pancreatic Neoplasms
| Article | Year |
|---|---|
Blocking IL-6/GP130 Signaling Inhibits Cell Viability/Proliferation, Glycolysis, and Colony Forming Activity in Human Pancreatic Cancer Cells.
Topics: Animals; Apoptosis; Cell Proliferation; Colony-Forming Units Assay; Cytokine Receptor gp130; Glycolysis; Humans; Indoles; Interleukin-6; Mice; Pancreatic Neoplasms; Selective Estrogen Receptor Modulators; Tumor Cells, Cultured | 2019 |
Blocking Interleukin-6 and Interleukin-8 Signaling Inhibits Cell Viability, Colony-forming Activity, and Cell Migration in Human Triple-negative Breast Cancer and Pancreatic Cancer Cells.
Topics: Benzamides; Cell Line, Tumor; Cell Movement; Cell Proliferation; Cell Survival; Cyclobutanes; Drug Synergism; Female; Humans; Indoles; Interleukin-6; Interleukin-8; Neoplastic Stem Cells; Pancreatic Neoplasms; Signal Transduction; Sulfonamides; Triple Negative Breast Neoplasms | 2018 |
Bazedoxifene as a Novel GP130 Inhibitor for Pancreatic Cancer Therapy.
Topics: Animals; Antineoplastic Agents; Apoptosis; Bone Density Conservation Agents; Cell Line, Tumor; Cell Survival; Cytokine Receptor gp130; Cytokines; Disease Models, Animal; Female; Humans; Indoles; Mice; Models, Molecular; Molecular Conformation; Pancreatic Neoplasms; Phosphorylation; Protein Binding; Selective Estrogen Receptor Modulators; Signal Transduction; STAT Transcription Factors; Xenograft Model Antitumor Assays | 2016 |